BGMS

#4899
Bio Green Med Solution, Inc. - Common Stock
0.8 6 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.86
0.86
Jahresspanne
0.57
6.70
Tagesänderung
-3.37%
Monatliche Änderung
-1.15%
6 month change
-10.06%
Jahresänderung
-85.67%
Vorheriger Schlusskurs
0.8 9
Open
0.8 6
Tief
0.8 6
Hoch
0.8 6
Volumen
3
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Bio Green Med Solution, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Bio Green Med Solution, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Bio Green Med Solution, Inc. current report, Q1 FY2026
8-K

Bio Green Med Solution, Inc. current report, Q4 FY2010

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Cyclacel Pharmaceuticals, Inc. on October 6, 2010, regarding events occurring on October 4, 2010. The filing addresses a special meeting of holders of the Company's 6% Exchangeable Convertible Preferred Stock.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance events related to Preferred Stockholders.

Material Changes and Events

  • Trigger for Meeting: The Company failed to pay dividends on its Preferred Stock for six quarterly periods, a condition that accrued rights to Preferred Stockholders to nominate and elect two directors to the Board as of August 2, 2010.
  • Meeting Outcome: The special meeting held on October 4, 2010, was adjourned because a quorum of Preferred Stockholders was not present in person or by proxy.
  • Voting Results: The adjournment was approved by a vote of 324,678 shares of Preferred Stock, with no shares voted against.
  • Rescheduled Meeting: The adjourned meeting is scheduled for November 1, 2010, at 1:00 p.m. at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. in New York, New York.

Guidance, Outlook, and Risks

The filing does not contain financial guidance, management commentary on future operations, or specific risk factors beyond the implication of the dividend default. The primary contingency noted is the upcoming November 1, 2010, meeting where the election of two directors will be attempted.

Investor Verification Checklist

  • Verify the Company's current dividend payment status and total arrears on the 6% Exchangeable Convertible Preferred Stock.
  • Confirm the attendance and voting results of the rescheduled meeting on November 1, 2010.
  • Identify the specific nominees proposed by Preferred Stockholders for the two director seats.
  • Review the Certificate of Designations for the Preferred Stock to understand the full scope of rights triggered by the dividend default.